About this trial
The Supersaturated Hydrogen-Rich Water for Outpatients with Persistent Excess Weight (HOPE) study is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of daily consumption of supersaturated hydrogen-rich water in adults with persistent excess body weight. The trial investigates whether sustained exposure to molecular hydrogen can favorably influence body composition and key metabolic outcomes compared with a placebo water lacking dissolved hydrogen. By enrolling outpatients across multiple centers and applying rigorous blinding and randomization procedures, HOPE aims to generate high-quality clinical evidence on the potential role of hydrogen-rich water as a non-pharmacological, adjunctive strategy for weight management and metabolic health.
Eligibility criteria
Qualifiers
Age > 18 years
Body mass index > 25.0 kg/m2 (persisted for at least six months before screening)
Stable on their therapy (if any) for ≥ 3 months
Free of acute disorders and severe chronic diseases
Disqualifiers
History of dietary supplement use 4 weeks before the study commences
Abnormal values for lab clinical chemistry not related with stiyd outcomes (> 2 SD)
No consent to randomization
Unwillingness to return for follow-up analysis
Trial design
Treatments tested in this trial
- Hydrogen-rich water
- Control